

Eiichi Kodama

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5564840/publications.pdf>

Version: 2024-02-01

95
papers

4,192
citations

94433

37
h-index

118850

62
g-index

96
all docs

96
docs citations

96
times ranked

3834
citing authors

#	ARTICLE	IF	CITATIONS
1	Study Profile of the Tohoku Medical Megabank Community-Based Cohort Study. <i>Journal of Epidemiology</i> , 2021, 31, 65-76.	2.4	81
2	Pyrimidine Analogues as a New Class of Gram-Positive Antibiotics, Mainly Targeting Thymineless-Death Related Proteins. <i>ACS Infectious Diseases</i> , 2020, 6, 1490-1500.	3.8	10
3	Cohort Profile: Tohoku Medical Megabank Project Birth and Three-Generation Cohort Study (TMM) <i>Tj ETQq1 1 0.784314 rgBT /Overlo</i> 2020, 49, 18-19m.	1.9	107
4	Application of human lymphoid cells for the evaluation of antivirals against human adenovirus type 19: Zalcitabine has superior activity compared to cidofovir. <i>Antiviral Chemistry and Chemotherapy</i> , 2020, 28, 204020662092131.	0.6	3
5	Synthetic biology based construction of biological activity-related library of fungal decalin-containing diterpenoid pyrones. <i>Nature Communications</i> , 2020, 11, 1830.	12.8	64
6	Design and Progress of Oral Health Examinations in the Tohoku Medical Megabank Project. <i>Tohoku Journal of Experimental Medicine</i> , 2020, 251, 97-115.	1.2	3
7	Mitochondrial dysfunction underlying sporadic inclusion body myositis is ameliorated by the mitochondrial homing drug MA-5. <i>PLoS ONE</i> , 2020, 15, e0231064.	2.5	15
8	Construction of a Meroterpenoid-Like Compounds Library Based on Diversity-Enhanced Extracts. <i>Chemistry - A European Journal</i> , 2019, 25, 1106-1112.	3.3	14
9	Identification of human immunodeficiency virus type-1 Gag-TSG101 interaction inhibitors by high-throughput screening. <i>Biochemical and Biophysical Research Communications</i> , 2018, 503, 2970-2976.	2.1	6
10	A Novel Peptide Derived from the Fusion Protein Heptad Repeat Inhibits Replication of Subacute Sclerosing Panencephalitis Virus In Vitro and In Vivo. <i>PLoS ONE</i> , 2016, 11, e0162823.	2.5	11
11	A Cinnamon-Derived Procyanidin Compound Displays Anti-HIV-1 Activity by Blocking Heparan Sulfate- and Co-Receptor- Binding Sites on gp120 and Reverses T Cell Exhaustion via Impeding Tim-3 and PD-1 Upregulation. <i>PLoS ONE</i> , 2016, 11, e0165386.	2.5	29
12	Structural basis of HIV inhibition by translocation-defective RT inhibitor 4-ethynyl-2-fluoro-2-deoxyadenosine (EFdA). <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 9274-9279.	7.1	73
13	Inhibition of the DNA polymerase and RNase H activities of HIV-1 reverse transcriptase and HIV-1 replication by <i>Brasenia schreberi</i> (Junsai) and <i>Petasites japonicus</i> (Fuki) components. <i>Journal of Natural Medicines</i> , 2015, 69, 432-440.	2.3	8
14	Use of a biosynthetic intermediate to explore the chemical diversity of pseudo-natural fungal polyketides. <i>Nature Chemistry</i> , 2015, 7, 737-743.	13.6	74
15	Histone chaperone CAF-1 mediates repressive histone modifications to protect preimplantation mouse embryos from endogenous retrotransposons. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 14641-14646.	7.1	68
16	Synthesis of a Vpr-Binding Derivative for Use as a Novel HIV-1 Inhibitor. <i>PLoS ONE</i> , 2015, 10, e0145573.	2.5	5
17	Delayed Emergence of HIV-1 Variants Resistant to 4-Ethyl-2-Fluoro-2-Deoxyadenosine: Comparative Sequential Passage Study with Lamivudine, Tenofovir, Emtricitabine and BMS-986001. <i>Antiviral Therapy</i> , 2014, 19, 179-189.	1.0	44
18	Current research on chronic active Epstein-Barr virus infection in Japan. <i>Pediatrics International</i> , 2014, 56, 159-166.	0.5	71

#	ARTICLE	IF	CITATIONS
19	4â€²-Ethynyl-2-fluoro-2â€²-deoxyadenosine (EFdA) Inhibits HIV-1 Reverse Transcriptase with Multiple Mechanisms. <i>Journal of Biological Chemistry</i> , 2014, 289, 24533-24548.	3.4	80
20	Hypersusceptibility mechanism of Tenofovir-resistant HIV to EFdA. <i>Retrovirology</i> , 2013, 10, 65.	2.0	36
21	Effects of Substitutions at the 4â€² and 2 Positions on the Bioactivity of 4â€²-Ethynyl-2-Fluoro-2â€²-Deoxyadenosine. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 6254-6264.	3.2	35
22	Mechanism of resistance to S138A substituted enfuvirtide and its application to peptide design. <i>International Journal of Biochemistry and Cell Biology</i> , 2013, 45, 908-915.	2.8	6
23	HIV-1 Resistance Mechanism to an Electrostatically Constrained Peptide Fusion Inhibitor That Is Active against T-20-Resistant Strains. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 4035-4038.	3.2	6
24	Evaluation of Combinations of 4â€²-Ethynyl-2-Fluoro-2â€²-Deoxyadenosine with Clinically Used Antiretroviral Drugs. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 4554-4558.	3.2	21
25	Development of Small Molecule HIV-1 Fusion Inhibitors: Linking Biology to Chemistry. <i>Current Pharmaceutical Design</i> , 2013, 19, 1827-1834.	1.9	9
26	Development and application of fluorescent SDF-1 derivatives. <i>Future Medicinal Chemistry</i> , 2012, 4, 837-844.	2.3	4
27	HIV-1 Reverse Transcriptase (RT) Polymorphism 172K Suppresses the Effect of Clinically Relevant Drug Resistance Mutations to Both Nucleoside and Non-nucleoside RT Inhibitors. <i>Journal of Biological Chemistry</i> , 2012, 287, 29988-29999.	3.4	9
28	Biochemical, inhibition and inhibitor resistance studies of xenotropic murine leukemia virus-related virus reverse transcriptase. <i>Nucleic Acids Research</i> , 2012, 40, 345-359.	14.5	14
29	A simple, rapid, and sensitive system for the evaluation of anti-viral drugs in rats. <i>Biochemical and Biophysical Research Communications</i> , 2012, 424, 257-261.	2.1	9
30	K70Q Adds High-Level Tenofovir Resistance to â€œQ151M Complexâ€•HIV Reverse Transcriptase through the Enhanced Discrimination Mechanism. <i>PLoS ONE</i> , 2011, 6, e16242.	2.5	29
31	Potent Anti-HIV-1 Activity of N-HR-Derived Peptides Including a Deep Pocket-Forming Region without Antagonistic Effects on T-20. <i>Antiviral Chemistry and Chemotherapy</i> , 2011, 22, 51-55.	0.6	3
32	Binding of Multivalent Anionic Porphyrins to V3 Loop Fragments of an HIVâ€1 Envelope and Their Antiviral Activity. <i>Chemistry - an Asian Journal</i> , 2010, 5, 825-834.	3.3	11
33	Characterization of HIV-1 resistance to a fusion inhibitor, N36, derived from the gp41 amino-terminal heptad repeat. <i>Antiviral Research</i> , 2010, 87, 179-186.	4.1	17
34	Resistance Profiles of Novel Electrostatically Constrained HIV-1 Fusion Inhibitors. <i>Journal of Biological Chemistry</i> , 2010, 285, 39471-39480.	3.4	37
35	The N348I Mutation at the Connection Subdomain of HIV-1 Reverse Transcriptase Decreases Binding to Nevirapine. <i>Journal of Biological Chemistry</i> , 2010, 285, 38700-38709.	3.4	41
36	Procyanidin B1 Purified from <i>Cinnamomi Cortex</i> Suppresses Hepatitis C Virus Replication. <i>Antiviral Chemistry and Chemotherapy</i> , 2010, 20, 239-248.	0.6	29

#	ARTICLE	IF	CITATIONS
37	Rev-derived peptides inhibit HIV-1 replication by antagonism of Rev and a co-receptor, CXCR4. <i>International Journal of Biochemistry and Cell Biology</i> , 2010, 42, 1482-1488.	2.8	6
38	Synthesis and biological evaluation of selective CXCR4 antagonists containing alkene dipeptide isosteres. <i>Organic and Biomolecular Chemistry</i> , 2010, 8, 616-621.	2.8	71
39	Affinity selection and sequence-activity relationships of HIV-1 membrane fusion inhibitors directed at the drug-resistant variants. <i>MedChemComm</i> , 2010, 1, 276.	3.4	3
40	SC29EK, a Peptide Fusion Inhibitor with Enhanced α -Helicity, Inhibits Replication of Human Immunodeficiency Virus Type 1 Mutants Resistant to Enfuvirtide. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 1013-1018.	3.2	82
41	Design of Peptide-based Inhibitors for Human Immunodeficiency Virus Type 1 Strains Resistant to T-20*. <i>Journal of Biological Chemistry</i> , 2009, 284, 4914-4920.	3.4	41
42	Mechanism of Inhibition of HIV-1 Reverse Transcriptase by 4'-Ethynyl-2-fluoro-2'-deoxyadenosine Triphosphate, a Translocation-defective Reverse Transcriptase Inhibitor. <i>Journal of Biological Chemistry</i> , 2009, 284, 35681-35691.	3.4	117
43	Synonymous mutations in stem-loop III of Rev responsive elements enhance HIV-1 replication impaired by primary mutations for resistance to enfuvirtide. <i>Antiviral Research</i> , 2009, 82, 67-72.	4.1	25
44	Clinical relevance of substitutions in the connection subdomain and RNase H domain of HIV-1 reverse transcriptase from a cohort of antiretroviral treatment-naïve patients. <i>Antiviral Research</i> , 2009, 82, 115-121.	4.1	38
45	Bioorganic synthesis of a recombinant HIV-1 fusion inhibitor, SC35EK, with an N-terminal pyroglutamate capping group. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 7964-7970.	3.0	11
46	Design and synthesis of membrane fusion inhibitors against the feline immunodeficiency virus. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 4916-4920.	3.0	5
47	Bioorganic synthesis of end-capped anti-HIV peptides by simultaneous cyanocysteine-mediated cleavages of recombinant proteins. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 7487-7492.	3.0	8
48	Electrostatically constrained α -helical peptide inhibits replication of HIV-1 resistant to enfuvirtide. <i>International Journal of Biochemistry and Cell Biology</i> , 2009, 41, 891-899.	2.8	59
49	X-ray Crystallographic Study of an HIV-1 Fusion Inhibitor with the gp41 S138A Substitution. <i>Journal of Molecular Biology</i> , 2009, 392, 657-665.	4.2	15
50	Peptide bond mimicry by (E)-alkene and (Z)-fluoroalkene peptide isosteres: synthesis and bioevaluation of α -helical anti-HIV peptide analogues. <i>Organic and Biomolecular Chemistry</i> , 2009, 7, 2872.	2.8	105
51	Elvitegravir: A New HIV Integrase Inhibitor. <i>Antiviral Chemistry and Chemotherapy</i> , 2009, 20, 79-85.	0.6	86
52	Development of a Novel Fusion Inhibitor against T-20-resistant HIV-1. <i>Advances in Experimental Medicine and Biology</i> , 2009, 611, 389-391.	1.6	1
53	Synthesis and Application of Fluorescein- and Biotin- Labeled Molecular Probes for the Chemokine Receptor CXCR4. <i>ChemBioChem</i> , 2008, 9, 1154-1158.	2.6	39
54	Identification of minimal sequence for HIV-1 fusion inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 9184-9187.	3.0	25

#	ARTICLE	IF	CITATIONS
55	Identification of novel non-peptide CXCR4 antagonists by ligand-based design approach. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 4124-4129.	2.2	29
56	Novel screening systems for HIV-1 fusion mediated by two extra-virion heptad repeats of gp41. <i>Antiviral Research</i> , 2008, 80, 71-76.	4.1	8
57	2-Deoxy-4-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants. <i>International Journal of Biochemistry and Cell Biology</i> , 2008, 40, 2410-2420.	2.8	114
58	Design of a Novel HIV-1 Fusion Inhibitor That Displays a Minimal Interface for Binding Affinity. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 388-391.	6.4	55
59	Dual-Reporter Phenotypic Assay for Human Immunodeficiency Viruses. <i>Journal of Clinical Microbiology</i> , 2008, 46, 792-795.	3.9	4
60	Binding Modes of Two Novel Non-Nucleoside Reverse Transcriptase Inhibitors, YM-215389 and YM-22855, to HIV Type-1 Reverse Transcriptase. <i>Antiviral Chemistry and Chemotherapy</i> , 2008, 19, 133-141.	0.6	2
61	Heptad Repeat-Derived Peptides Block Protease-Mediated Direct Entry from the Cell Surface of Severe Acute Respiratory Syndrome Coronavirus but Not Entry via the Endosomal Pathway. <i>Journal of Virology</i> , 2008, 82, 588-592.	3.4	42
62	Amino Acid Mutation N348I in the Connection Subdomain of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confers Multiclass Resistance to Nucleoside and Nonnucleoside Reverse Transcriptase Inhibitors. <i>Journal of Virology</i> , 2008, 82, 3261-3270.	3.4	88
63	Broad Antiretroviral Activity and Resistance Profile of the Novel Human Immunodeficiency Virus Integrase Inhibitor Elvitegravir (JTK-303/GS-9137). <i>Journal of Virology</i> , 2008, 82, 764-774.	3.4	330
64	2-Deoxy-4-C-Ethynyl-2-Fluoroadenosine: A Nucleoside Reverse Transcriptase Inhibitor with Highly Potent Activity Against Wide Spectrum of HIV-1 Strains, Favorable Toxic Profiles, and Stability in Plasma. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2007, 26, 1543-1546.	1.1	49
65	Activity against Human Immunodeficiency Virus Type 1, Intracellular Metabolism, and Effects on Human DNA Polymerases of 4-Ethynyl-2-Fluoro-2-Deoxyadenosine. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 2701-2708.	3.2	96
66	Novel HIV-1 Integrase Inhibitors Derived from Quinolone Antibiotics. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 1506-1508.	6.4	311
67	A Novel Colorimetric Assay for CXCR4 and CCR5 Tropic Human Immunodeficiency Viruses. <i>Antiviral Chemistry and Chemotherapy</i> , 2006, 17, 215-223.	0.6	9
68	Structural Basis for the Interaction of CCR5 with a Small Molecule, Functionally Selective CCR5 Agonist. <i>Journal of Immunology</i> , 2006, 177, 3116-3122.	0.8	31
69	Creation of Low Toxic Reverse-transcriptase Inhibitory Nucleosides that Prevent the Emergence of Drug-resistant HIV Variants. <i>Yuki Gosei Kagaku Kyokaiishi/Journal of Synthetic Organic Chemistry</i> , 2006, 64, 716-723.	0.1	10
70	Studies of non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 2: Synthesis and structure-activity relationships of 2-cyano and 2-hydroxy thiazolidenebenzenesulfonamide derivatives. <i>Bioorganic and Medicinal Chemistry</i> , 2005, 13, 949-961.	3.0	24
71	RNase S complex bearing arginine-rich peptide and anti-HIV activity. <i>Journal of Molecular Recognition</i> , 2005, 18, 169-174.	2.1	7
72	Mutations Conferring Resistance to Human Immunodeficiency Virus Type 1 Fusion Inhibitors Are Restricted by gp41 and Rev-Responsive Element Functions. <i>Journal of Virology</i> , 2005, 79, 764-770.	3.4	87

#	ARTICLE	IF	CITATIONS
73	Halogenated Thymidine Analogues Restore the Expression of Silenced Genes without Demethylation. <i>Cancer Research</i> , 2005, 65, 6927-6933.	0.9	15
74	Novel patterns of nevirapine resistance-associated mutations of human immunodeficiency virus type 1 in treatment-naïve patients. <i>Virology</i> , 2004, 327, 215-224.	2.4	16
75	Studies of nonnucleoside HIV-1 reverse transcriptase inhibitors. Part 1: Design and synthesis of thiazolidenebenzenesulfonamides. <i>Bioorganic and Medicinal Chemistry</i> , 2004, 12, 6171-6182.	3.0	16
76	Design, Efficient Synthesis, and Anti-HIV Activity of 4â€²-Cyano- and 4â€²-Ethynyl-2â€²-deoxy Purine Nucleosides, Nucleotides and Nucleic Acids, 2004, 23, 671-690.	1.1	44
77	Broad spectrum anti-RNA virus activities of titanium and vanadium substituted polyoxotungstates. <i>Antiviral Research</i> , 2003, 58, 265-271.	4.1	127
78	Synthesis of 4â€²-C-Ethynyl and 4â€²-C-Cyano Purine Nucleosides from Natural Nucleosides and Their Anti-HIV Activity. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2003, 22, 887-889.	1.1	4
79	Remodeling of gp41-C34 Peptide Leads to Highly Effective Inhibitors of the Fusion of HIV-1 with Target Cells We thank Dr. Terrence R. Burke, Jr., NCI, NIH, Frederick, MD 21702-1201, for proofreading the manuscript and providing useful comments. This research was supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan, the Japan Society for the Promotion of Science, and the Japan Health Science Foundation.. <i>Angewandte Chemie International Edition</i> , 2004, 43, 2754-2758.	13.8	157
80	Development of specific CXCR4 inhibitors possessing high selectivity indexes as well as complete stability in serum based on an anti-HIV peptide T140. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2001, 11, 1897-1902.	2.2	115
81	4â€²-Ethynyl Nucleoside Analogs: Potent Inhibitors of Multidrug-Resistant Human Immunodeficiency Virus Variants In Vitro. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 1539-1546.	3.2	137
82	Antileukemic activity and mechanism of action of cordycepin against terminal deoxynucleotidyl transferase-positive (TdT+) leukemic cells. <i>Biochemical Pharmacology</i> , 2000, 59, 273-281.	4.4	110
83	Syntheses of 4â€²-C-Ethynyl-Î²-d-arabino- and 4â€²-C-Ethynyl-2â€²-deoxy-Î²-d-ribo-pentofuranosylpyrimidines and -purines and Evaluation of Their Anti-HIV Activity. <i>Journal of Medicinal Chemistry</i> , 2000, 43, 4516-4525.	6.4	84
84	Interactions of Conformationally Biased North and South 2â€²-Fluoro-2â€²,3â€²-dideoxynucleoside 5â€²-Triphosphates with the Active Site of HIV-1 Reverse Transcriptase. <i>Biochemistry</i> , 2000, 39, 11205-11215.	2.5	27
85	In Vitro Anti-Human Immunodeficiency Virus Activities of Z - and E -Methylenecyclopropane Nucleoside Analogues and Their Phosphoro- Alaninate Diesters. <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 1487-1490.	3.2	36
86	In Vitro Induction of Human Immunodeficiency Virus Type 1 Variants Resistant to Phosphoralaninate Prodrugs of Z -Methylenecyclopropane Nucleoside Analogues. <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 2479-2483.	3.2	41
87	Characterization of Human Immunodeficiency Virus Type 1 Strains Resistant to the Non-Nucleoside Reverse Transcriptase Inhibitor RD4â€²2217. <i>Antiviral Chemistry and Chemotherapy</i> , 1999, 10, 315-320.	0.6	6
88	Anti-Herpesvirus Activities and Cytotoxicities of 2-Thiopyrimidine Nucleoside Analogues in Vitro. <i>Antiviral Chemistry and Chemotherapy</i> , 1999, 10, 195-209.	0.6	25
89	Inhibition of Human Immunodeficiency Virus Replication by RD6-Y664, a Novel Benzylhydroxylamine Derivative. <i>Antiviral Chemistry and Chemotherapy</i> , 1999, 10, 71-77.	0.6	8
90	Application of a gastric cancer cell line (MKN-28) for anti-adenovirus screening using the MTT method. <i>Antiviral Research</i> , 1996, 31, 159-164.	4.1	54

#	ARTICLE	IF	CITATIONS
91	Antiviral Activity of a Sulphated Polysaccharide Extracted from the Marine Pseudomonas and Marine Plant Dinoflagellata against Human Immunodeficiency Viruses and other Enveloped Viruses. Antiviral Chemistry and Chemotherapy, 1996, 7, 189-196.	0.6	9
92	Evaluation of Antiherpetic Compounds Using a Gastric Cancer Cell Line: Pronounced Activity of BVDU against Herpes Simplex Virus Replication. Microbiology and Immunology, 1996, 40, 359-363.	1.4	6
93	Detection of antibodies to 65 KD heat shock protein and to human superoxide dismutase in autoimmune hepatitis-molecular mimicry between 65 KD heat shock protein and superoxide dismutase. Clinical Rheumatology, 1995, 14, 673-677.	2.2	22
94	Analysis of mutations in the thymidine kinase gene of varicella zoster virus associated with resistance to 5-iodo-2-deoxyuridine and 5-bromo-2-deoxyuridine. Antiviral Research, 1995, 27, 165-170.	4.1	4
95	Detection of hepatitis C virus genome in human serum by multi-targeted polymerase chain reaction. Journal of Medical Virology, 1993, 41, 6-10.	5.0	11